Patents by Inventor Odile Filhol

Odile Filhol has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER
    Publication number: 20230278983
    Abstract: The present invention relates to indole derivatives of formula (I?) as CK2 inhibitor and pharmaceutical compositions comprising the same. The present invention further relates to the use of such compounds of formula (I) for use for preventing and/or treating a cancer.
    Type: Application
    Filed: July 6, 2021
    Publication date: September 7, 2023
    Applicants: Universite Claude Bernard Lyon 1, Institut National de la Sante et de la Recherche Madicale, Centre National de la Recherche Scientifique, Ecole Normale Superieure de Lyon, Commissariat à l'Energie Atomique et aux Energies AlternativesS, Centre Leon Berard
    Inventors: Alexandre Bancet, Claude Cochet, Odile Filhol-Cochet, Isabelle Krimm, Thierry Lomberget, Marc Le Borgne
  • Methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway
    Patent number: 11629192
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: April 18, 2023
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITÉ PARIS CITÉ, FONDATION IMAGINE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE GRENOBLE ALPES, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, UNIVERSITE DE BOURGOGNE
    Inventors: Zakia Belaid-Choucair, Olivier Hermine, Carmen Garrido-Fleury, Claude Cochet, Odile Filhol-Cochet, Renaud Seigneuric
  • METHOD FOR DETERMINING THE INVASIVE POTENTIAL OF A TUMOR CELL
    Publication number: 20200102590
    Abstract: The present invention relates to a method for predicting the invasive potential of a tumor cell and predicting the efficiency of a treatment. The method is based on the combination of at least three parameters, namely the internuclear distance, the polarization and the cell-cell connectivity.
    Type: Application
    Filed: May 30, 2018
    Publication date: April 2, 2020
    Inventors: MANUEL THERY, YORAN MARGARON, ODILE FILHOL-COCHET
  • Synthetic lethal drug combination for treating renal cell carcinoma
    Patent number: 10322133
    Abstract: The present invention pertains to a novel treatment of renal cell carcinoma and other a solid tumors which harbor a VHL inactivation, based on the combination of a first agent inhibiting a protein kinase CK2 (CK2) and a second agent inhibiting an Ataxia Telangiectasia Mutated (ATM) kinase.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: June 18, 2019
    Assignees: Commissariat a l'Energie Atomique et aux Energies Alternatives, Institut National de la Sante et de la Recherche Medicale
    Inventors: Sofia Giacosa, Catherine Pillet, Claude Cochet, Odile Filhol, Caroline Barette, Emmanuelle Soleilhac
  • Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway
    Publication number: 20190002569
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.
    Type: Application
    Filed: September 4, 2018
    Publication date: January 3, 2019
    Inventors: Zakia Belaid-Choucair, Olivier Hermine, Carmen Garrido-Fleury, Claude Cochet, Odile Filhol-Cochet, Renaud Seigneuric
  • A Synthetic Lethal Drug Combination for Treating Renal Cell Carcinoma
    Publication number: 20180256587
    Abstract: The present invention pertains to a novel treatment of renal cell carcinoma and other a solid tumors which harbor a VHL inactivation, based on the combination of a first agent inhibiting a protein kinase CK2 (CK2) and a second agent inhibiting an Ataxia Telangiectasia Mutated (ATM) kinase.
    Type: Application
    Filed: September 21, 2016
    Publication date: September 13, 2018
    Applicants: Commissariat a l'Energie Atomique et aux Energies Alternatives, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Sofia Giacosa, Catherine Pillet, Claude Cochet, Odile Filhol, Caroline Barette, Emmanuelle Soleilhac
  • Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway
    Publication number: 20170051062
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.
    Type: Application
    Filed: February 18, 2015
    Publication date: February 23, 2017
    Inventors: Zakia Belaid-Choucair, Olivier Hermine, Carmen Garrido-Fleury, Claude Cochet, Odile Filhol-Cochet, Renaud Seigneuric
  • In vitro method for diagnosing prostate cancer
    Patent number: 8829162
    Abstract: The invention relates to an in vitro method for diagnosing prostate cancer and to antibodies and fragments thereof directed against CK2-? and their use for the diagnosis and prognosis of prostate cancer.
    Type: Grant
    Filed: January 2, 2008
    Date of Patent: September 9, 2014
    Assignees: Inserm (Institut National de la Sante et de la Recherche Medicale), Commissariat a l'Energie Atomique
    Inventors: Claude Cochet, Odile Filhol, Mathieu Laramas
  • Small interfering RNA specific to sub-units ?, ??and ? of the Kinase Protein ck2, and the applications of the same
    Patent number: 8106179
    Abstract: The invention relates to small interfering RNA specific to sub-units ?, ?? and ? of the kinase protein CK2, and to the applications of the same, especially for treating cancer and viral illnesses.
    Type: Grant
    Filed: July 2, 2004
    Date of Patent: January 31, 2012
    Assignees: Commissariat a l'Energie Atomique, Institut National de la Sante et de la Recherche Medicale
    Inventors: Béatrice Schaack, Claude Cochet, Odile Filhol-Cochet, Brigitte Fouque
  • In Vitro Method for Diagnosing Prostate Cancer
    Publication number: 20100136576
    Abstract: The invention relates to an in vitro method for diagnosing prostate cancer and to antibodies and fragments thereof directed against CK2-? and their use for the diagnosis and prognosis of prostate cancer.
    Type: Application
    Filed: January 2, 2008
    Publication date: June 3, 2010
    Applicant: COMMISSARIAT A L'ENERGIE ATOMIQUE
    Inventors: Claude Cochet, Odile Filhol, Mathieu Laramas
  • Small Interfering RNA Specific to Sub-Units $g(a),$g(a)' and $g(b) of the Kinase Protein ck2,and the Applications of the Same
    Publication number: 20070219148
    Abstract: The invention relates to small interfering RNA specific to sub-units ?, ? and ? of the kinase protein CK2, and to the applications of the same, especially for treating cancer and viral illnesses.
    Type: Application
    Filed: July 2, 2004
    Publication date: September 20, 2007
    Applicants: Commissariat A L'energie Atomique, Institut Nat De La Sante et De La Recherche Med
    Inventors: Beatrice Schaack, Claude Cochet, Odile Filhol-Cochet, Brigitte Fouque